Products

CaviWipes 2.0

CaviWipes 2.0 by Metrex

Product Options:

CaviWipes 2.0 by Metrex
12 canisters/cs (160 wipes/canister):
Part # ACP141100CS case $146.00

CaviWipes 2.0 is a multi-purpose disinfectant for use in cleaning and disinfecting hard, non-porous, inanimate surfaces and non-critical instruments in hospitals, laboratories and other critical care areas where environmental control of cross-contamination between treated surfaces is important.

 

CAVIWIPES 2.0 SURFACE DISINFECTION TOWELETTES FEATURES & BENEFITS:

  • 2-minute universal contact time for bacteria, viruses, and pathogenic fungi (Candida auris)
  • Proven effective against SARS-CoV-2 on hard non-porous surfaces
  • 1 step disinfecting (if no visible debris present on surface)
  • Effective against 60 relevant pathogens including Norovirus and Candida auris for added confidence in preventing healthcare associated infections.
  • Excellent Material Compatibility – Compatible with most non-porous, hard surfaces commonly used in clinical settings

 

QUALIFICATIONS:

  • EPA’s Emerging Viral Pathogens claim for all virus types (enveloped, large and small non-enveloped viruses) to meet current and potentially future infection prevention needs
  • On EPA List Q

 

CAVIWIPES 2.0 SURFACE DISINFECTION TOWELETTES LIST OF USES:

  • Ambulance equipment surfaces
  • Animal care facilities
  • Bathrooms
  • Correctional facilities
  • Daycare centers
  • Dental offices
  • Emergency medical settings
  • Emergency vehicles
  • Exterior surfaces of anesthesia machines and respiratory therapy equipment
  • Health club facilities
  • Hospitals
  • Infant/child care equipment surfaces
  • Interior and exterior surfaces of infant incubators, bassinets
  • Isolation areas
  • Laboratories
  • Laundry rooms
  • Neonatal units
  • Nursing homes
  • Operating rooms
  • Ophthalmic and optometric facilities
  • Outpatient surgical centers
  • Oxygen hoods
  • Schools
  • Surgical centers

 

CAVIWIPES 2.0 SURFACE DISINFECTION TOWELETTES KILL CLAIMS:

2 Minute Efficacy Against

  • Adenovirus Type 2
  • Echovirus Type 11
  • Enterovirus Type 71
  • Human Rotavirus
  • Norovirus
  • Adenovirus Type 5
  • Rhinovirus Type 1A
Pathogenic Fungi
  • Candida auris
Multi-Drug-Resistant Bacteria
  • Penicillin-Resistant Streptococcus pneumoniae (PRSP)
  • Vancomycin-Resistant Enterococcus faecalis (VRE)
  • Methicillin-Resistant Staphylococcus aureus (MRSA)
  • Carbapenem-resistant Klebsiella pneumoniae (CRKP)
  • Multidrug-Resistant Acinetobacter baumannii (MRAB)
  • NDM-1 Enterobacter cloacae
  • Vancomycin-Intermediate Staphylococcus aureus (VISA)
  • Methicillin-Resistant Staphylococcus epidermidis
  • Multi-Drug Resistant Pseudomonas aeruginosa
  • ESBL Klebsiella pneumoniae
  • ESBL Escherichia coli
Bacteria
  • Acinetobacter baumannii
  • Bordetella pertussis
  • Burkholderia cepacia
  • Enterococcus faecium
  • Escherichia coli O157:H7
  • Klebsiella pneumoniae
  • Legionella pneumophila
  • Micrococcus luteus
  • Moraxella catarrhalis
  • Pseudomonas aeruginosa
  • Salmonella enterica
  • Staphylococcus aureus
  • Stenotrophomonas maltophilia
  • Streptococcus mutans
  • Streptococcus pyogenes
  • Klebsiella aerogenes
  • Serratia marcescens
  • Campylobacter jejuni
  • Listeria monocytogenes
  • Shigella dysenteriae
  • Chlamydophila pneumoniae
  • Flavobacterium columnare
  • Mycobacterium tuberculosis (TB)
Enveloped Viruses
  • Herpes simplex virus Type 1
  • Herpes simplex virus Type 2
  • Influenza A virus
  • Varicella-zoster virus
  • Cytomegalovirus
  • SARS-associated Coronavirus
  • SARS-CoV-2
  • SARS-CoV-2-UK Variant
  • SARS-CoV-2 South African Variant
  • SARs-CoV-2-California Variant
  • SARS-CoV-2 Delta Variant
  • Influenza B virus
  • Parainfluenza virus Type 3
  • Human orthopneumovirus
  • Measles virus
  • Hepatitis C Virus (HCV)
  • Hepatitis B Virus (HBV)
  • Human Immunodeficiency Virus Type 1 (HIV-1)